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Abstract
Tamoxifen (Tm)-inducible Cre recombinases are widely used to perform gene inactivation and lineage tracing studies in
mice. Although the efficiency of inducible Cre-loxP recombination can be easily evaluated with reporter strains, the precise
length of time that Tm induces nuclear translocation of CreER
Tm and subsequent recombination of a target allele is not well
defined, and difficult to assess. To better understand the timeline of Tm activity in vivo, we developed a bioassay in which
pancreatic islets with a Tm-inducible reporter (from Pdx1
PB-CreER
Tm;R26R
lacZ mice) were transplanted beneath the renal
capsule of adult mice previously treated with three doses of 1 mg Tm, 8 mg Tm, or corn oil vehicle. Surprisingly,
recombination in islet grafts, as assessed by expression of the b-galactosidase (b-gal) reporter, was observed days or weeks
after Tm treatment, in a dose-dependent manner. Substantial recombination occurred in islet grafts long after
administration of 368 mg Tm: in grafts transplanted 48 hours after the last Tm injection, 77.960.4% of b-cells were b-gal+;
in b-cells placed after 1 week, 46.265.0% were b-gal+; after 2 weeks, 26.367.0% were b-gal+; and after 4 weeks, 1.960.9%
were b-gal+. Islet grafts from mice given 361 mg Tm showed lower, but notable, recombination 48 hours (4.961.7%) and 1
week (4.561.9%) after Tm administration. These results show that Tm doses commonly used to induce Cre-loxP
recombination may continue to label significant numbers of cells for weeks after Tm treatment, possibly confounding the
interpretation of time-sensitive studies using Tm-dependent models. Therefore, investigators developing experimental
approaches using Tm-inducible systems should consider both maximal recombination efficiency and the length of time that
Tm-induced Cre-loxP recombination occurs.
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Introduction
The advent of tamoxifen (Tm)-inducible Cre recombinases has
greatly improved the ability to temporally control Cre-loxP
recombination in vivo, and has been particularly useful for
investigating properties of mature tissues in the adult mouse.
Over the past decade, Tm-inducible gene recombination has been
used to examine organ maintenance and function through a
variety of approaches, including cell lineage tracing [1–12],
inducible gene expression [13–17], and gene inactivation [18–21].
Several studies have described the importance of various
parameters in Cre-loxP recombination, such as expression of
Cre recombinase [22,23] and the accessibility of loxP sites [24,25].
For inducible Cre-loxP recombination, one critical parameter that
is often poorly described is verification that the Tm dose used is
appropriate for the experiment, not only for maximizing the
spatial extent of recombination in the target tissue but also by
limiting the temporal extent of recombination. Specifically,
knowing the timeline of Tm-induced Cre-loxP recombination is
critical for ‘‘pulse-chase’’ lineage tracing experiments, because a
pulse that unknowingly extends into the chase period will continue
to label newly generated cells, and lead to the interpretation that
all labeled cells are derived from the cell population that existed
during the expected pulse period. For example, the current limited
knowledge of the Tm pulse period in adult mice may be one factor
contributing to the discrepancies observed in recent lineage tracing
studies of the pancreas.
In the pancreatic islet biology field, investigators are striving to
understand the normal development and maintenance of insulin-
producing b-cells and attempting to find sources for creating and
regenerating b-cells, with the ultimate goal of treating diabetes.
The use of Tm-inducible mouse models for cell lineage tracing has
played a key role in advancing our understanding of pancreas
biology, although some conflicting results have yet to be resolved.
In an adaptation of classic pulse-chase experiments, Dor and
colleagues were the first to use a Tm-inducible Cre driver strain to
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determining that the proportion of labeled b-cells did not change
over time, they concluded that pre-existing b-cells were the source
of b-cell replenishment in adult mice, and that there was no
significant contribution of (unlabeled) stem cells to the b-cell
population. This finding was also supported by studies using Tm-
inducible systems to demonstrate that all mature b-cells possess a
certain replication capacity [27–29]. In contrast, several other
groups have used the same pulse-chase approach and concluded
that b-cells can originate from non-b-cell sources, after observing
changes in the proportion of labeled b-cells following post-injury
regeneration or during pregnancy, when b-cell mass increases
[30–32]. Further complicating our concept of b-cell turnover, one
group reported isolating multipotent, stem-like cells from pancre-
atic islets, and, using the same lineage tracing methods as Dor et
al., identified insulin+ cells as the source [33].
An alternative lineage tracing approach is to label a given cell
type and determine whether or not it has the capacity to mature or
transdifferentiate into another cell type. Using this more direct
method of tracking cells, b-cells have been reported to originate
from pancreatic ductal cells [34] and glucagon-producing a-cells
[35] in the injured mature pancreas, suggesting that transdiffer-
entiation may occur under specific circumstances. However, the
mechanisms involved in this process still require further examina-
tion, as several studies have failed to find evidence of b-cell
transdifferentiation from acinar cells [36–40] or ductal cells [41–
44] in the adult pancreas.
While the Tm-inducible genetic models used in these studies
have proven to be useful in addressing complex biological
questions regarding pancreas development and maintenance, the
conflicting results are sometimes difficult to reconcile. The fact
that various Cre driver mice and reporter strains were used makes
it inherently more difficult to compare different studies, as each
model system differs in the specificity of Cre expression and the
efficiency of target gene induction [45–47]. A recent report that
described Tm-independent activity of Cre recombinase in the
commonly used b-cell-targeted RIP-CreER
Tm mouse found that the
extent of the ‘‘leakiness’’ varied, depending on the target gene
[48]. Moreover, a wide range of Tm doses and administration
methods have been reported, even for studies using similar Cre
driver and reporter mice. In fact, one review questioned whether
different Tm doses could account for the conflicting outcomes in
two very similar models of pancreatic ductal cell lineage tracing
[46]. The need to draw such comparisons between experiments
emphasizes the necessity for a full understanding of the parameters
controlling recombination in each model system.
While understanding the temporal limits of CreER activity is
crucial for the design and interpretation of lineage tracing
experiments, the kinetics of Tm activity have been studied almost
exclusively in embryonic tissues [49,50]. Using immunohisto-
chemistry, it was found that Cre localized to the nucleus of
embryonic cells 24 hours after administration of Tm to a pregnant
dam, but returned to the cytoplasm 48 hours after treatment [49].
Further studies showed that the extent of recombination events
was dramatically different in embryos depending on the
developmental stage at which Tm treatment was performed, due
to the embryo’s rapidly changing gene expression profile. These
results suggested that Tm-induced recombination events in the
embryo are restricted to a short time frame after drug
administration to the dam [50–52]. Since most tissues in the adult
animal do not show frequent, dramatic changes in gene expression
or cell turnover, it is not possible to extrapolate the duration of
active recombination following Tm administration in embryonic
studies to that in adult mice.
In this study, we defined the kinetics of Tm-induced Cre-loxP
recombination in pancreatic b-cells in adult mice. Because the
precise level of circulating Tm necessary for inducing recombina-
tion in vivo is unknown, we used pancreatic islet transplantation as
a bioassay to directly measure recombination at a given time
following Tm administration. We found that significant recombi-
nation of reporter alleles can occur for weeks after Tm treatment,
and that the length of time that a Tm pulse induces recombination
is dose-dependent. Furthermore, we observed side effects in Tm-
treated male mice that have not been reported in recent literature.
These data have considerable implications for the design and
interpretation of studies utilizing Tm-inducible systems in adult
mice.
Methods
Ethics Statement
Animal studies were performed according to guidelines in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. Animal protocols were approved by the Institutional
Animal Care and Use Committee at Vanderbilt University
Medical Center (Animal Welfare Assurance Number A3227-01).
Surgeries were performed under ketamine/xylazine anesthesia,
and all efforts were made to minimize pain and suffering.
Mice
For the islet transplantation bioassay, male hemizygous
transgenic Pdx1
PB-CreER
Tm [53] mice were bred with female
R26R
lacZ reporter mice (Jackson Laboratory, [54]) for one or two
generations to obtain mice hemizygous for the Cre transgene and
heterozygous or homozygous for the R26R
lacZ reporter allele. For
studies on Cre subcellular localization in the pancreas, we used
Pdx1
PB-CreER
Tm mice that had been crossed with mice expressing
a conditional (‘‘floxed’’) Vegfa allele, Vegfa
loxP [55]. For initial
experiments, we also used RIP-CreER
Tm mice [26]. PCR
genotyping was performed on tail biopsies with primers described
[54–56]. A summary of the mouse strains used, along with the
Mouse Genome Informatics (MGI) nomenclature, is shown in
Table S1.
Tamoxifen preparation and administration
Corn oil (Sigma C8267) was sterilized using a Steriflip vacuum-
assisted filter unit (Millipore). Tamoxifen (Tm, Sigma T5648) was
dissolved in filter-sterilized corn oil to make solutions of 10 mg/ml
or 20 mg/ml, which were subsequently protected from light. Tm
solutions were freshly prepared the day prior to each injection and
placed on a nutator to dissolve overnight at room temperature.
Before treatment, excess fur was shaved from the backs of recipient
mice under isoflurane anesthesia. Recipient mice were then given
subcutaneous injections of 1 mg Tm (100 ml volume), 8 mg Tm
(400 ml volume), or corn oil vehicle every 48 hours, for a total of 3
doses over a 5-day period. Injection sites were sealed with Vetbond
tissue adhesive (3 M) to prevent oil leakage. Following Tm or
vehicle administration, mice were housed individually to prevent
cross-contamination [57].
Islet isolation and transplantation
Islet transplant experiments were performed with littermate
donors and recipients, between 6 and 17 weeks of age. Islets were
isolated from donor mice by collagenase P digestion [58] and
handpicked to near 100% purity with microscopic guidance.
Littermate recipient mice were anesthetized with a mixture of
90 mg/kg ketamine and 10 mg/kg xylazine (Henry Schein,
Melville, NY) before islet transplantation was performed, as
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from one donor mouse were transplanted under the kidney
capsule of a single littermate recipient mouse either 48 hours,
1 week, 2 weeks, or 4 weeks after the final Tm or vehicle injection.
Graft-bearing kidneys were harvested two weeks after islet
transplantation.
Tissue collection, immunohistochemistry, X-gal staining,
and imaging
Islet graft-bearing kidneys and whole pancreata were dissected
in ice-cold 10 mM PBS, fixed in 4% paraformaldehyde,
equilibrated in 30% w/w sucrose, and frozen in Tissue-Tek
Optimal Cutting Temperature compound (VWR Scientific
Products, Willard, OH) before cryosectioning (detailed in [58]).
Five-mm cryosections were labeled by immunohistochemistry as
described previously [58], using the following primary antibodies:
guinea pig anti-human insulin IgG (Linco Research, St. Charles,
MO; diluted 1:200), rabbit anti-b-galactosidase IgG (ICN
Pharmaceuticals, Costa Mesa, CA; 1:10000), and rabbit anti-Cre
recombinase IgG (EMD4Biosciences, formerly Novagen;
1:10000). Secondary antibodies conjugated to Cy2 or Cy3
fluorophores were obtained from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Slides with immunolabeled
tissue were mounted with SlowFade Gold antifade reagent with
DAPI nuclear counterstain (Invitrogen, Carlsbad, CA) before
imaging. b-galactosidase activity was also assessed in tissue
cryosections by X-gal staining, as described previously [58].
Tissue images were acquired using an Olympus BX41 fluores-
cence microscope (Olympus; Tokyo, Japan) and a Zeiss LSM 510
Meta laser scanning confocal microscope (Carl Zeiss; Jena,
Germany).
Reproductive organs dissected from Tm- and vehicle-treated
mice were fixed in 4% paraformaldehyde and dehydrated in an
ethanol series (35%, 50%, and 70% for 30 minutes each) before
embedding in paraffin. Five-mm sections were stained with
hematoxylin and eosin. Tissue images were acquired with a
ScanScope CS slide scanner (Aperio Technologies, Inc., Vista,
CA).
Quantification of recombined cells
Insulin+ and b-galactosidase+ (b-gal+) cells were counted
manually with the aid of MetaMorph software (Universal Imaging,
Downington, PA). At least three cross-sections were counted for
each islet graft (200–3000 total insulin+ cells counted per graft),
and at least ten islet cross-sections were counted per pancreas
(300–500 insulin+ cells counted per mouse). The percentage of
insulin+ b-cells expressing b-gal was calculated for each cross-
section, and averaged for each graft or pancreas sample. Two to
four tissue samples were obtained for each treatment group or time
point.
Results
Tamoxifen-induced Cre-loxP recombination in pancreatic
b-cells
Our interest in tamoxifen (Tm)-inducible systems began when
developing a model in which we could inactivate production of
vascular endothelial growth factor A (VEGF-A) by pancreatic islets
in the adult mouse to evaluate its effects on islet vascularization and
function. We initiated these experiments using two different mouse
strains to target expression of a Tm-inducible Cre recombinase to
pancreatic b-cells of adult mice, namely the RIP-CreER
Tm [26] and
Pdx1
PB-CreER
Tm [53] driver strains. As reported previously [48], we
found that RIP-CreER
Tm;R26R
lacZ islets showed significant expres-
sion of the b-galactosidase reporter in the absence of Tm (Figure
S1). Therefore, for subsequent experiments we used Pdx1
PB-
CreER
Tm mice, crossed to the R26R
lacZ reporter strain or to a strain
containing a conditional Vegfa allele (Vegfa
loxP, [55]).
Tamoxifen-induced nuclear localization of Cre
recombinase is time- and dose-dependent
To estimate the duration of Tm-induced Cre-mediated
recombination in adult mice, we first evaluated nuclear localiza-
tion of Cre recombinase in islet b-cells on pancreatic sections
collected from transgenic Pdx1
PB-CreER
Tm;Vegfa
loxP mice at differ-
ent time points following the administration of 368 mg Tm. This
dose effectively induced recombination of the floxed VEGF-A
allele, as assessed by ELISA: islets isolated from Pdx1
PB-
CreER
Tm;Vegfa
loxP mice showed significantly reduced VEGF-A
secretion one week and one month following Tm treatment
(Figure S2).
Surprisingly, Cre was found in the b-cell nucleus and cytoplasm
in Pdx1
PB-CreER
Tm;Vegfa
loxP pancreas collected either one week or
one month after the final Tm dose (Figure 1D–I). In contrast,
vehicle-treated Pdx1
PB-CreER
Tm;Vegfa
loxP mice displayed strict
cytoplasmic localization of Cre in b-cells, as demonstrated by
colocalization with insulin (Figure 1A–C). Likewise, b-cells from
Pdx1
PB-CreER
Tm;Vegfa
loxP mice sacrificed three months after the
final Tm treatment demonstrated cytoplasmic but not nuclear Cre
localization (Figure 1J–L). Extended nuclear localization of Cre
was also observed five weeks after administration of 268m gT m
to Pdx1
PB-CreER
Tm;R26R
lacZ reporter mice, as demonstrated by
colocalization of Cre and the nuclear marker DAPI in b-cells
(Figure S3D–F). However, Pdx1
PB-CreER
Tm;R26R
lacZ mice given
168 mg Tm showed cytoplasmic Cre localization at this time
point (Figure S3A–C).
Higher doses of tamoxifen induce recombination weeks
following administration
To better understand how long a given Tm dose is able to
induce Cre-mediated recombination in vivo, we developed a system
that would allow us to evaluate recombination that occurs at any
given time following Tm treatment. We reasoned that measuring
the serum Tm concentration in this model would likely be
unhelpful, because the precise level of circulating Tm necessary for
inducing recombination is unknown. Therefore, we designed a
bioassay using pancreatic islet transplantation to assess recombi-
nation in Tm-naı ¨ve islet b-cells transplanted into Tm-treated mice.
In this model, islets containing a Tm-inducible Cre reporter (from
Pdx1
PB-CreER
Tm;R26R
lacZ mice) were transplanted beneath the
renal capsule of mice treated with different doses of Tm prior to
islet transplantation (Figures 2A and 3A). In this way, the relevant
endpoint, recombination, served as the metric.
We first evaluated a dose of 368 mg Tm, a dose similar to that
used in other studies for lineage tracing of b-cells in adult mice
[26–28,30–33,35]. As expected, islets in Tm-treated R26R
lacZ mice
did not express b-gal, as visualized by immunohistochemistry
(Figure 2B). In Pdx1
PB-CreER
Tm;R26R
lacZ mice given 368 mg Tm,
80.168.2% of b-cells in pancreatic islets expressed b-gal
(Figure 2C). To evaluate this dose in the transplant model,
recipient mice were given three subcutaneous injections of Tm or
vehicle before receiving a pancreatic islet transplant from Tm-
naı ¨ve Pdx1
PB-CreER
Tm;R26R
lacZ donor mice. Islet grafts were
placed 48 hours, 1 week, 2 weeks, or 4 weeks following the final
Tm injection (Figure 2A). We observed significant recombination
in Pdx1
PB-CreER
Tm;R26R
lacZ islet grafts in mice given 368m gT m
for weeks after the final Tm dose. When quantified, 77.960.4% of
Tamoxifen-Induced Recombination in Adult Mice
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Tm injection (Figure 2F, Figure S4E–F), 46.265.0% were b-gal+
1 week after injection (Figure 2G, Figure S4G–H), and
26.367.0% expressed b-gal 2 weeks after injection (Figure 2H,
Figure S4I–J). Recombination was also noted in grafts placed 4
weeks after the final Tm injection, with 1.960.9% of b-cells
positive for b-gal (Figure 2I, Figure S4K–L). In contrast, islet cells
from R26R
lacZ mice transplanted into Tm-treated mice did not
express b-gal (Figure 2D, Figure S4A–B). Similarly, most Pdx1
PB-
CreER
Tm;R26R
lacZ islet cells transplanted into vehicle-treated mice
did not show signs of recombination (Figure 2E, Figure S4C–D),
although a few b-gal+ b-cells were found in one of the grafts
(0.660.6%). These results were confirmed by X-gal staining
(Figure 2J–O, Figure S5).
Lower doses of tamoxifen induce recombination up to
one week following administration
Next, we used the islet transplantation bioassay to test the
duration of recombination following 361 mg Tm (Figure 3A), a
dose that also induced effective recombination in Pdx1
PB-CreER
Tm;
Vegfa
loxP mice (manuscript in preparation). Compared to mice
receiving 368 mg Tm, treatment with 361 mg Tm induced less
recombination in pancreatic islets of Pdx1
PB-CreER
Tm;R26R
lacZ mice
(29.864.1% of b-cells expressed b-gal, Figure 3B). Likewise, we
observed less, but notable, recombination in Pdx1
PB-CreER
Tm;R26R
lacZ
grafts placed in mice receiving 361m gT m :4 . 9 61.7% of b-cells
expressed b-gal 48 hours after Tm (Figure 3E, Figure S6E–F), and
4.561.9% of b-cells were b-gal+ 1 week after Tm (Figure 3F, Figure
S6G–H). No b-gal+ b-cells were noted in control grafts (Figure 3C–D,
Figure S6A–D). These results were also confirmed byX-gal staining of
the islet grafts (Figure 3G–J, Figure S7).
Duration of tamoxifen-induced gene recombination is
dose-dependent
A summary of Tm-induced recombination in Pdx1
PB-
CreER
Tm;R26R
lacZ pancreatic islets and islet grafts is shown in
Figure 4. Recombination of b-cells in both endogenous pancreatic
islets (Figure 4A) and in islet grafts (Figure 4B) is dose-dependent.
At either dose, recombination in the transplanted islet cells was
lower than recombination in pancreatic islets. However, all groups
of Pdx1
PB-CreER
Tm;R26R
lacZ islets transplanted into Tm-treated
mice showed recombination rates higher than vehicle-treated
controls, independent of Tm dose or time of transplantation.
While recombination in Pdx1
PB-CreER
Tm;R26R
lacZ islet grafts from
mice receiving 361 mg Tm was relatively low at both the 48-hour
and 1-week post-treatment time points, compared to islets in the
pancreas of mice receiving 361 mg Tm, the recombination seen
in Pdx1
PB-CreER
Tm;R26R
lacZ islet grafts from mice receiving
368 mg Tm was substantial for 2 weeks following Tm
administration (Figure 4B). Importantly, Pdx1
PB-CreER
Tm;R26R
lacZ
islet grafts from mice treated with 368 mg Tm showed
recombination at a rate higher than controls even 4 weeks after
treatment (Figure 4B). The estimated kinetics of Tm-induced
recombination in our model system are plotted in Figure 4C.
Long-term side effects of tamoxifen treatment
At both doses, we observed major side effects in Tm-treated
mice that have not been mentioned in recent publications. The
corn oil vehicle itself was incompletely absorbed in some mice, as
indicated by subcutaneous masses found in the area of injection in
both vehicle-treated and Tm-treated mice (Figure S8A). Upon
dissection, these masses contained pockets of transparent oil, with
no signs of inflammation or infection. Oil pockets were especially
Figure 1. Tamoxifen-induced Cre subcellular localization is time-dependent. Representative islets from adult Pdx1
PB-CreER
Tm;Vegfa
loxP mice
given 8 mg tamoxifen (Tm, D–L) or corn oil vehicle (A–C) in three subcutaneous injections. Pancreata were harvested 1 week (D–F), 1 month (G–I),
or 3 months (J–L) following the last injection and labeled with antibodies against insulin (green; A, D, G, J) and Cre recombinase (red; B, E, H, K).
Merged images are shown in C, F, I, L. Scale bar in A is 50 mm, and applies to panels B–L.
doi:10.1371/journal.pone.0033529.g001
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administration. Additionally, male mice treated with Tm, but not
corn oil vehicle alone, experienced dramatic scrotal enlargement
(Figure S8B). This enlargement was first observed one week after
Tm administration and lasted for at least three months (our last
observed time point). Almost all of the .100 male mice we have
treated with Tm developed this abnormality to some degree.
While higher Tm doses did cause more dramatic anatomic
changes, variability was seen between mice given identical doses.
Some mice were more bothered by the scrotal changes, and
developed self-inflicted wounds. Upon dissection, no changes were
observed in the size of male reproductive organs or perigonadal fat
pads. However, the fat appeared to envelop the testes more loosely
in Tm-treated mice, and in some cases, loops of intestine were
found to extend into the scrotum, indicating herniation.
Histological examination of the male reproductive tract revealed
no changes in reproductive organs, such as testis and epididymis,
following Tm treatment (Figure S8C–D). Instead, Tm-treated
males showed patches of edematous reactive fat containing spindle
cells (Figure S8F). One mouse with extensive self-inflicted wounds
showed chronic inflammation and fat necrosis within the preputial
gland, located in the subcutaneous tissue adjacent to the penis
(Figure S8H).
Discussion
Tm-inducible Cre-loxP systems are being used in broad areas of
research and are providing important biologic insights in tissue
development, maintenance, and function. However, our under-
standing of the parameters involved in recombination is
incomplete. One unresolved issue regarding Cre-loxP recombina-
tion in adult mice is the length of time that Tm induces
recombination. In this study, we developed an in vivo bioassay
using pancreatic islet transplantation to directly measure recom-
Figure 2. Higher dose tamoxifen induces recombination weeks following administration. A. Islets from untreated Pdx1
PB-CreER
Tm;R26R
lacZ
mice or R26R
lacZ controls were transplanted into mice given three subcutaneous injections of 8 mg tamoxifen (Tm) or corn oil vehicle at the indicated
times following the last injection. Pancreata and islet grafts were harvested 2 weeks after the final injection. B–C. Representative pancreatic islets
from R26R
lacZ (Cre2) mice (B)o rPdx1
PB-CreER
Tm;R26R
lacZ (Cre+) mice (C) treated with 368 mg Tm. Cryosections were labeled with antibodies to
insulin (green; B, C) and b-galactosidase (b-gal, red; B, B9, C, C9). Scale bar in B is 50 mm, and applies to panels B9, C, and C9. D–I. Islet graft
cryosections were labeled with antibodies to insulin (green; D–I) and b-gal (red; D–I, D9–I9). Scale bar in D is 50 mm, and applies to panels E–I, D9–I9.
J–O. b-gal activity was tested in islet grafts using X-gal. Scale bar in J is 100 mm, and applies to panels K–O. Images of the full graft cross-sections
(before cropping and rotating for visual clarity) are shown in Figures S4 and S5.
doi:10.1371/journal.pone.0033529.g002
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quantifying the biologic and pharmacologic half-life of Tm. We
found that: (1) administration of high Tm doses leads to extended
CreER nuclear localization; (2) Tm administration induces
reporter gene recombination for several days or weeks after Tm
treatment is completed, depending on the original dose adminis-
tered; and (3) Tm treatment induces side effects that may have
physiologic consequences in Tm-inducible models.
Multiple factors are involved in obtaining specific and effective
Cre-loxP recombination in vivo, including (but not limited to) the
promoter or enhancer driving expression of Cre recombinase, the
accessibility of loxP sites in the target gene, and, for inducible
systems, the Tm dose used [23,48,49,59]. First, the chosen
promoter or enhancer in a Cre driver mouse ideally targets Cre
expression to specific cell types; in reality, transgenic mice do not
express Cre in 100% of the targeted cells, and some transgenes
Figure 3. Lower dose tamoxifen induces recombination up to one week following administration. A. Islets from untreated Pdx1
PB-
CreER
Tm;R26R
lacZ (Cre+) mice or R26R
lacZ (Cre2) controls were transplanted into mice given three subcutaneous injections of 1 mg tamoxifen (Tm) or
corn oil vehicle at the indicated times following the last injection. Pancreata and islet grafts were harvested 2 weeks after the final injection. B.
Representative islet from a Cre+ mouse treated with 361 mg Tm, labeled with antibodies to insulin (green; B) and b-galactosidase (b-gal, red; B, B9).
Scale bar in B is 50 mm, and applies to panel B9. C–F. Islet graft cryosections were labeled with antibodies to insulin (green; C–F) and b-gal (red; C-F,
C9–F9). Scale bar in C is 50 mm, and applies to panels D–F, C9–F9. G–J. b-gal activity was tested in islet grafts using X-gal. Scale bar in G is 100 mm,
and applies to panels H–J. Images of the full graft cross-sections (before cropping and rotating for visual clarity) are shown in Figures S6 and S7.
doi:10.1371/journal.pone.0033529.g003
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Second, the accessibility of target loxP alleles to Cre recombinase
can also impact recombination efficiency. For example, recombi-
nation of the Z/AP and Z/EG reporters is less efficient than
recombination of reporter alleles in the ROSA26 locus [25,61], and
studies with these reporters may not necessarily reflect recombi-
nation of other target alleles [48]. Third, in addition to the wide
range of Tm doses reported in the literature, there are a variety of
Tm administration methods, from the use of Tm or its active
metabolite 4-hydroxytamoxifen, to the drug preparation (oil
suspensions vs. implanted pellets), and the route of administration
(subcutaneous vs. intraperitoneal vs. oral). Finally, our bioassay
data demonstrates that the duration of Tm activity is another
important variable to consider for Tm-inducible systems. In all,
this wide range in model systems and methodology makes it
difficult to compare different studies, and may contribute to the
conflicting results reported in the pancreatic b-cell literature.
We developed this bioassay to directly assess the length of time
that a given dose of Tm can induce Cre-loxP recombination in vivo.
Early studies on Tm-induced Cre-loxP recombination utilized the
rapid turnover of keratinocytes in epidermis to show that induction
of reporter gene expression was limited to a few days after
administrationofrelatively lowdosesofTm[22,62].Reporter gene-
expressing keratinocytes that originated in the basal epidermal layer
were found to have migrated out within one week of stopping Tm
treatment, leaving unlabeled, newly generated cells below. Addi-
tionally, subcellular localization of Cre recombinase was correlated
with Tm administration, as Cre was found in the keratinocyte
nucleus in mice currently undergoing Tm treatment, but was
localized to the cytoplasm three days after the final Tm dose.
In contrast to the doses used in those early experiments to
evaluate the timeline of Tm activity in skin (which were similar to
the low dose used in our bioassay) [22,62], many recent studies
have used much higher Tm doses to achieve maximal recombi-
nation of reporter alleles in target tissues [6–10,12]. The rationale
for using a higher Tm dose in studies utilizing Tm-inducible
models in the pancreas [26–28,30–33,35] include: (1) the
transgenic mice commonly used to target pancreatic b-cells (RIP-
CreER
Tm [26] and Pdx1
PB-CreER
Tm [53]) were generated using the
CreER
Tm sequence [51], which has been shown to be less sensitive
to Tm than the CreER
T2 sequence [63]; and (2) recombination
efficiency is influenced by the accessibility of target loxP alleles to
Cre recombinase [48]. The Z/AP reporter mouse has been
frequently used to label pancreatic b-cells, and recombination of
the Z/AP and Z/EG reporter alleles is less efficient than
recombination of reporter alleles in the ROSA26 locus [25].
Although using the Tm dose that allows for maximal recombina-
tion is desirable, our data show that high doses of Tm can induce a
prolonged period of Tm-induced Cre activity and unwanted side
effects. Therefore, determining the optimal Tm dose for efficacy
and safety will be particularly important in characterizing new
model systems, including the recently described MIP-CreER mouse
that targets b-cells [60].
We examined the subcellular localization of Cre recombinase to
estimate the time frame of potential recombination following Tm
treatment. The fact that Cre was detected in nuclei of b-cells in the
pancreas up to five weeks following the final Tm dose suggested
that administration of Tm to adult mice induces a period of
recombination that is much longer than the 12- to 48-hour
window originally described in Tm-treated embryos [49,50,52].
Indeed, we observed significant Tm-induced recombination up to
four weeks following drug administration, though perhaps to a
lower extent than the number of b-cells showing nuclear
localization of Cre might suggest. There are several possible
reasons for this discrepancy in Cre subcellular localization and
target gene recombination. We analyzed Cre localization in
endogenous b-cells in the pancreas of transgenic mice, while the
islet grafts had been transplanted under the kidney capsule of
Figure 4. Duration of tamoxifen-induced gene recombination
is dose-dependent. The percentage of insulin+ b-cells expressing b-
gal in islets from pancreas sections (A) and from transplanted islet
grafts (B) is shown. Each data point represents the percentage of
double-positive cells to all insulin+ b-cells counted in a single mouse
sample. Cre2, R26R
lacZ control islets; Cre+, Pdx1
PB-CreER
Tm;R26R
lacZ
islets; Tm, tamoxifen. C. Amount of recombination observed in islet
grafts from mice given either 361m go r3 68 mg tamoxifen at the
indicated time points following the last tamoxifen injection. Data in C is
expressed as means of data in B.
doi:10.1371/journal.pone.0033529.g004
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these two sites, as the pancreas was found to have unexpectedly
high concentrations of Tm compared to other tissues [64,65].
Additionally, the low blood flow experienced by newly transplant-
ed islets may reduce the amount of Tm circulating to the b-cells, as
revascularization of islet grafts takes several days to weeks to occur
[58]. For these reasons, our islet graft model may in fact
underestimate the amount of recombination that may occur in
endogenous b-cells of Tm-treated mice. Alternatively, there may
not be a direct correlation between Cre localization and
recombination of target alleles; however, this is difficult to assess,
as the amount of nuclear Cre required for inducing recombination
is dependent on the sensitivity of the targeted floxed allele [25,48],
and may not necessarily be detected by immunohistochemistry.
Importantly, our data shows that evaluating Cre subcellular
localization alone is not sufficient to estimate active recombination
in a given cell.
We administered Tm subcutaneously, as other groups have
reported without noting side effects [28,44,66]. While unexpected,
the oil pockets we observed are consistent with a report that
described incomplete absorption of oil vehicles after an attempt to
administer hormones subcutaneously to rodents [67]. In that
study, the investigators collected the subcutaneous oil that
remained days or weeks after injection and found that it still
contained biologically active estrins. This observation raises the
possibility that Tm itself is slowly and/or incompletely absorbed
following subcutaneous injection, which could lead to the
prolonged biologic activity we observed in this study, and
potentially to variability in Tm dosing between mice. Alternative
Tm administration methods, such as implanted or food-based
pellets, will prevent side effects associated with the oil vehicle.
However, the length of Tm action must still be determined for
each of these treatment protocols.
The side effects that we observed in Tm-treated male mice were
also surprising, because there has been little discussion of adverse
events following Tm administration to adult transgenic mice
[24,68–70]. The pathologic changes in the scrota of Tm-treated
mice appear to be limited to fat (and in one case, the preputial
gland), and not to male reproductive organs. Instead, the scrotal
swelling in Tm-treated mice closely resembles the scrotal hernias
observed in male mice treated with estrogenic compounds, which
were associated with hypertrophy of inguinal and scrotal skeletal
muscle [71–73]. As Tm has mainly estrogenic actions in mice [64],
the hernias may be an indication that Tm treatment is promoting
feminization of male mice. This is potentially concerning for
investigators using these models for studies on metabolic diseases
like diabetes. It is well known that wild-type male and female mice
show differences in glucose tolerance [74,75], and some recent
studies have reported that male mice are more susceptible to
developing glucose intolerance following Cre-loxP-mediated inac-
tivation of critical b-cell genes such as FoxM1 and Ngn3 [76,77].
Thus, it is important not only to include Tm-treated control groups
to evaluate the drug’s physiologic effects on the mice, but also to
limit the Tm dose in order to minimize these effects.
In summary, we observed a prolonged period of Tm-induced
nuclear localization of Cre recombinase, accompanied by
significant levels of Cre-loxP recombination days and weeks after
Tm treatment. These findings have important implications for the
design and interpretation of experiments utilizing Tm-inducible
systems. While a prolonged period of recombination is not
necessarily undesirable in studies in which Tm is used to inactivate
target genes, it is a critical parameter in lineage tracing
experiments that rely on the induction of a reporter gene during
a defined ‘‘pulse’’ period. Because many variables may affect Tm-
induced recombination in a given model, the doses and timeline
we describe cannot be applied as strict guidelines for all Tm-
inducible systems. Importantly, these data caution against the use
of high Tm doses with the expectation that the effects of Tm are
innocuous and short-lived. We recommend that investigators
carefully define the Tm dose and duration of action in each model
system.
Supporting Information
Figure S1 Tamoxifen-independent recombination in
RIP-CreER
Tm;R26R
lacZ mice. Pancreas was harvested from
adult RIP-CreER
Tm;R26R
lacZ mice not exposed to tamoxifen (Tm).
Immunofluorescence was performed on cryosections for insulin
(blue; A, C) and b-galactosidase (b-gal, red; B, C). Scale bar in A is
50 mm, and applies to panels B–C.
(TIF)
Figure S2 VEGF-A expression is significantly reduced in
Pdx1
PB-CreER
Tm;Vegfa
loxP islets after administration of
368 mg tamoxifen. Islets were isolated from adult Pdx1
PB-
CreER
Tm;Vegfa
loxP mice and Vegfa
loxP controls before tamoxifen (Tm)
treatment and 1 week and 1 month following 3 doses of 8 mg Tm.
Aliquots of 70 size-matched islets were cultured in 500 ml RPMI-
1640 media for 48 hours at 37uC, and VEGF-A in the cultured
media was measured by ELISA (R&D Systems) as described [78].
**P,0.0001.
(TIF)
Figure S3 Tamoxifen-induced Cre subcellular localiza-
tion is dose-dependent. Representative islets from adult
Pdx1
PB-CreER
Tm;R26R
lacZ mice given one (A–C) or two (D–F)
subcutaneous injections of 8 mg tamoxifen (Tm). Pancreata were
harvested 5 weeks following the last injection and labeled with
antibodies against insulin (green; C, F) and Cre recombinase (red;
B, C, E, F); DAPI nuclear stain (blue; A, C, D, F). Scale bar in A is
50 mm, and applies to panels B–F.
(TIF)
Figure S4 Higher dose tamoxifen induces recombina-
tion weeks following administration. Images of the full graft
cross-sections shown in Figure 2, before cropping and rotating for
visual clarity. Scale bar in A is 200 mm, and applies to panels B–L.
(TIF)
Figure S5 Higher dose tamoxifen induces recombina-
tion weeks following administration. Islets from untreated
Pdx1
PB-CreER
Tm;R26R
lacZ mice (Cre+)o rR26R
lacZ controls (Cre2)
were transplanted into mice given three subcutaneous injections of
8 mg tamoxifen (Tm) or corn oil vehicle at the indicated times
following the last injection. Islet grafts were harvested 2 weeks after
transplantation and subjected to X-gal staining (A, C, E, G, I, K,
M). Phase contrast images with color overlay are shown in B, D,
F, H, J, L, and N. Scale bar in A is 200 mm, and applies to panels
B–N. Panels C, E, G, I, K, and M are images of the full graft
cross-sections shown in Figure 2, before cropping and rotating for
visual clarity.
(TIF)
Figure S6 Lower dose tamoxifen induces recombination
up to one week following administration. Images of the full
graft cross-sections shown in Figure 3, before cropping and
rotating for visual clarity. Scale bar in A is 200 mm, and applies to
panels B–H.
(TIF)
Figure S7 Lower dose tamoxifen induces recombination
up to one week following administration. Islets from
Tamoxifen-Induced Recombination in Adult Mice
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33529untreated Pdx1
PB-CreER
Tm;R26R
lacZ mice (Cre+)o rR26R
lacZ
controls (Cre2) were transplanted into mice given three
subcutaneous injections of 1 mg tamoxifen (Tm) or corn oil
vehicle at the indicated times following the last injection. Islet
grafts were harvested 2 weeks after transplantation and subjected
to X-gal staining (A, C, E, G, I, K, M, O). Phase contrast images
with color overlay are shown in B, D, F, H, J, L, N, and P. Scale
bar in A is 200 mm, and applies to panels B–P. Panels E, G, I, K,
M, and O are images of the full graft cross-sections shown in
Figure 3, before cropping and rotating for visual clarity.
(TIF)
Figure S8 Side effects of tamoxifen treatment. A. Some
mice given subcutaneous injections of corn oil vehicle with or
without tamoxifen (Tm) had subcutaneous accumulation of oil
(white arrows) weeks and months following the last oil injection. B.
Tm-treated male mice demonstrated scrotal enlargement (black
arrows) as early as one week after treatment and lasting for
months. Tm-treated mice shown were given 368 mg Tm, but
similar results were observed in mice given 361 mg Tm. C–H.
H&E-stained sections of tissue from the scrota of control (C, E, G)
and Tm-treated (D, F, H) male mice. Images were acquired with
a ScanScope CS slide scanner. C–D. Seminiferous tubules of the
testes. Scale bar in D is 200 mm, and applies to panel C. E–F.
Scrotal fat in a control mouse (E), compared to the reactive fat
observed in a Tm-treated mouse (F). Scale bar in F is 200 mm, and
applies to panel E. G–H. One Tm-treated mouse showed chronic
inflammation and fat necrosis within the preputial gland (H);
control gland, G. Scale bar in H is 400 mm, and applies to panel
G.
(TIF)
Table S1 Summary of mouse strains.
(DOC)
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